PRRT2 and cancer: Currently, we can hypothesize that a coordinated inhibition of any of the following active molecules in the following cancer cells: cAMP, PKC, MEK/ERK, Hsp70, Hsc70, Hsp90, and mortalin, combined with complement-activating antibody, will amplify cancer cell death and increase the sensitivity of cancer to immunotherapy.